About this trial
A total of 220 patients (110 per arm) who report moderate alcohol consumption between 1 and 28 standard units (1 standard unit = \~10 grams) per week in the 12 months prior to hospital admission will be planned for randomization, using a 1:1 ratio to pursue moderate alcohol consumption (1 standard unit per day for women and 2 standard units per day for men) or abstinence (except for one drink on predefined/agreed special occasions) for a total duration of 3 months. An echocardiography will be performed at baseline and 3 months to assess changes in systolic cardiac function (LVEF) for the primary endpoint. A core laboratory team blinded to assignment will perform data interpretation.
Eligibility criteria
Qualifiers
Hospitalization for acute ST-elevation MI (STEMI) or non ST-elevation MI (NSTEMI) within 365 days prior to screening
Men and women aged ≥18 years who are capable and willing to provide consent
ECG ischemic changes, such as persistent or dynamic ST-segment deviation
Evidence of positive high-sensitive troponin
Disqualifiers
High alcohol consumption, defined as an average of >28 alcoholic standard units/week in the 12 months prior to the index hospitalization
Alcohol use disorder (AUDIT score >20 at screening)
History of alcohol or substance abuse
Naïve to alcohol consumption
Trial design
Treatments tested in this trial
- Alcohol consumption
Treatment groups
Locations
4Sponsors and collaborators
Baris Gencer
Lead sponsor
University Hospital, Geneva
Sponsor institution
University of Bern
Collaborator
Swiss National Science Foundation
Collaborator